- Home
- HSBC vs KZR Comparison
HSBC vs KZR Comparison
Compare HSBC & KZR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSBC
- KZR
- Stock Information
- Founded
- HSBC 1865
- KZR 2015
- Country
- HSBC United Kingdom
- KZR United States
- Employees
- HSBC N/A
- KZR N/A
- Industry
- HSBC Savings Institutions
- KZR Biotechnology: Pharmaceutical Preparations
- Sector
- HSBC Finance
- KZR Health Care
- Exchange
- HSBC Nasdaq
- KZR Nasdaq
- Market Cap
- HSBC 226.5B
- KZR 29.7M
- IPO Year
- HSBC N/A
- KZR 2018
- Fundamental
- Price
- HSBC $69.43
- KZR $3.91
- Analyst Decision
- HSBC Buy
- KZR Hold
- Analyst Count
- HSBC 1
- KZR 2
- Target Price
- HSBC N/A
- KZR $9.00
- AVG Volume (30 Days)
- HSBC 1.2M
- KZR 34.3K
- Earning Date
- HSBC 10-28-2025
- KZR 11-11-2025
- Dividend Yield
- HSBC 4.73%
- KZR N/A
- EPS Growth
- HSBC N/A
- KZR N/A
- EPS
- HSBC 1.00
- KZR N/A
- Revenue
- HSBC $56,208,000,000.00
- KZR N/A
- Revenue This Year
- HSBC $11.20
- KZR N/A
- Revenue Next Year
- HSBC $0.98
- KZR N/A
- P/E Ratio
- HSBC $69.52
- KZR N/A
- Revenue Growth
- HSBC N/A
- KZR N/A
- 52 Week Low
- HSBC $43.38
- KZR $3.62
- 52 Week High
- HSBC $69.47
- KZR $9.18
- Technical
- Relative Strength Index (RSI)
- HSBC 72.74
- KZR 43.94
- Support Level
- HSBC $63.55
- KZR $3.76
- Resistance Level
- HSBC $69.32
- KZR $4.09
- Average True Range (ATR)
- HSBC 0.63
- KZR 0.14
- MACD
- HSBC 0.39
- KZR 0.01
- Stochastic Oscillator
- HSBC 99.07
- KZR 38.46
About HSBC HSBC Holdings plc.
Established in 1865 in Hong Kong, London-based HSBC is one of the largest banks in the world, with assets of USD 3 trillion and 40 million customers worldwide. It operates in more than 50 countries with more than 200,000 full-time staff. The United Kingdom and Hong Kong are its two largest markets. The bank offers retail, commercial and institutional banking, global banking and markets, wealth management, and private banking.
About KZR Kezar Life Sciences Inc.
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.